Sanofi is collaborating with Blackstone Life Sciences to accelerate the development of a treatment for multiple myeloma.

Emmes has acquired Casimir, marking its fourth major acquisition.

Sanofi and Seagen have entered an agreement to investigate three cancer targets.

Catalent has announced the completion of a $30 million project at its facility in Limoges, France focused on biopharmaceutical development and drug product manufacturing.

Viatris’ new drug-device is the first FDA-approved generic version of AstraZeneca’s Symbicort.

BioMed X and Merck KGaA, Darmstadt, Germany announced their collaboration on a research project to study T-cells and autoimmunity.

Envirotainer and Swiss WorldCargo have successfully completed the first commercial shipment using a new temperature-controlled air freight solution.

Novasep increases its production capacity for HPAPIs with an investment in its site in Le Mans, France.

EMA has recommended that possible side effects of Spikevax and Janssen COVID-19 vaccines be added to product information.

ProteoGenix’s new XtenCHO Transient Expression can achieve up to ten times higher yields than market-leading CHO systems.

NIH has launched one of the first Phase 1 clinical trials to examine mRNA technology for HIV.

CDMO Almac Pharma Services expanded its European ultra-low temperature packaging capabilities.

The US Congress approved a federal spending package that increases funding for a range of programs to advance health and medicine.

Flow Eighteeen38 is receiving a €5 million (US$5.58 million) investment from its parent company, FairJourney Biologics.

Evitria has entered into an agreement with mAbsolve that will allow the company to use mAbsolve’s gene silencing technology in their antibody cells.

C4 Therapeutics has been granted orphan drug designation by FDA for CFT8634 for the treatment of soft tissue sarcoma.

SCG Cell Therapy has signed a collaboration agreement with A*STAR’s BTI to advance the development of antibodies for infectious diseases and cancer treatments.

Biotech companies and medical product manufacturers have condemned the invasion of Ukraine, while also looking to maintain supplies of essential medicines.

Novartis will pay Voyager up to $1.75 billion for access to Voyager’s novel Tracer AAV capsids for potential use with three CNS targets.

Various executives in the life sciences industry have started a petition calling for “complete economic disengagement” with Russia.

Novo Nordisk will expand its existing research collaboration in novel delivery technologies with MIT and Brigham and Women’s Hospital.

Evonik has launched new EUDRATEC technology to improve solubility and performance of oral small molecules.

Curia and the US government have entered into a cooperative agreement to expand fill/finish capability for injectable medicines.

UCB has announced it will build a new innovative gene therapy facility in Belgium.

Spectrum Chemical has further expanded its bioCERTIFIED product portfolio to support the growing global demand for new vaccines and therapeutics.

Amgen has announced the groundbreaking of its newest biomanufacturing facility in North Carolina.

Johnson & Johnson have announced a landmark agreement to enable the manufacturing and availability of its COVID-19 vaccine in Africa by an African company.

G-CON’s signature standardPOD cleanrooms will now be available in Europe.